Journal of nanobiotechnology

Engineered protein-based particles carrying risperidone for improved antipsychotic effects

Updated

Abstract

Risperidone-loaded proteinoid nanoparticles showed significantly higher antipsychotic activity compared to free risperidone.

  • Proteinoid polymers were synthesized using L-amino acids and poly-L-lactic acid through a specific polymerization process.
  • Risperidone was successfully encapsulated in proteinoid nanoparticles using a self-assembly method followed by surface modification.
  • Characterization of the nanoparticles included assessments of size, drug loading, and potential cytotoxicity.
  • The biodistribution and psychopharmacological effects of the drug-loaded nanoparticles were evaluated.
  • Encapsulation in proteinoid nanoparticles may enhance drug delivery and efficiency while potentially reducing necessary dosages and side effects.

Simplified

Key numbers

20%
Increase in Antipsychotic Activity
Optimal drug loading in RSP-loaded proteinoid NPs.
20 min
Blood Half-Life
Half-life of Cy7-conjugated proteinoid NPs in blood.
97±2 nm
Diameter of RSP-loaded NPs
Hydrodynamic diameter of Prot.1/RSP NPs.

Full Text

What this is

  • This research investigates a new drug delivery system using proteinoid nanoparticles (NPs) to enhance the efficacy of the antipsychotic drug risperidone (RSP).
  • Proteinoid NPs are designed to improve drug solubility and stability, potentially allowing for better targeting and reduced side effects.
  • The study demonstrates that RSP-loaded proteinoid NPs exhibit significantly higher antipsychotic activity compared to free RSP.

Essence

  • Proteinoid nanoparticles encapsulating risperidone enhance drug delivery and efficacy, showing improved antipsychotic effects compared to free risperidone.

Key takeaways

  • Proteinoid nanoparticles were synthesized from L-amino acids and poly-L-lactic acid, achieving high molecular weight and low polydispersity. These nanoparticles effectively encapsulated risperidone, enhancing its solubility and stability.
  • In vivo tests using an amphetamine-induced hyperactivity model showed that RSP-loaded proteinoid NPs reduced activity levels more effectively than free RSP, indicating improved antipsychotic efficacy.
  • The encapsulated RSP demonstrated a blood half-life of approximately 20 minutes, suggesting efficient distribution and potential for enhanced therapeutic effects through better brain targeting.

Caveats

  • The study primarily serves as proof of concept, and further research is needed to fully understand the dosage-response relationship and potential side effects of RSP-loaded proteinoid NPs.
  • Behavioral effects observed may also be influenced by sedation induced by antipsychotic drugs, which complicates the interpretation of results.

Definitions

  • Proteinoids: Random polymers synthesized from amino acids, resembling natural proteins and used in drug delivery systems.
  • PEGylation: The process of attaching polyethylene glycol (PEG) to molecules, enhancing their stability and circulation time in the bloodstream.

Simplified

Funding

Competing interests

The authors declare that they have no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free